This page is an historical document and contains content that may be out of date.
Dr. Martin H. Goldrosen Named Chief of NCCAM's Office of Scientific Review
For Immediate Release:
Bethesda, MD–Martin H. Goldrosen, Ph.D., was recently appointed chief of the Office of Scientific Review at the National Center for Complementary and Alternative Medicine (NCCAM), a component of the National Institutes of Health (NIH). The Office is responsible for the peer review of all grant applications assigned to NCCAM.
In his new role, Dr. Goldrosen will plan, lead, and direct the activities of scientists and technical support personnel within the Office to ensure quality, objectivity, and accountability in the grants and contracts peer review process. He will also direct and coordinate activities to evaluate the overall performance of NCCAM’s grant review processes and allocation of resources, as necessary to support changing workloads and funding mechanisms.
Rigorous, timely, and fair review of scientific applications has proven over the decades to be invaluable to the success of the NIH research mission. It is always an undertaking that must be conducted with meticulous integrity, attention to detail, and an understanding of the best and most current science. The process is particularly challenging in as new and controversial a discipline as complementary and alternative medicine (CAM). The selection of Dr. Goldrosen to direct NCCAM’s review efforts represents a commitment to attain and maintain the highest standards of peer review. “Dr. Goldrosen is an outstanding scientist-manager who brings a wealth of knowledge to NCCAM,” said Stephen E. Straus, M.D., NCCAM Director. “His background as a superb and well-funded investigator, and his proven expertise in the review of basic and applied research applications will prove invaluable to the Center’s mission,” Dr. Straus said.
Dr. Goldrosen began his NIH career in 1991 as a health scientist administrator within the Grants Review Branch of the Division of Extramural Affairs at the National Cancer Institute (NCI). While at NCI, he was responsible for the review of grant applications in the areas of drug development and biological response modifiers. He also oversaw the Specialized Program of Research Excellence and was in charge of the NCI-D Clinical Sciences Committee, which reviews translational and clinical program pilot grants. Dr. Goldrosen provided leadership and direction in the conduct of numerous grant review committee meetings and advised Scientific Review Administrators on unique problems associated with specific grant applications. In addition, he provided interim leadership for the NCI’s Research Programs Review Section and trained newly recruited Scientific Review Administrators in all facets of the review process.
Prior to NIH, Dr. Goldrosen was a Cancer Research Scientist at the Roswell Park Cancer Center in New York. His research interests were in the area of tumor immunobiology. He performed the first orthotopic transplant procedure in mice, which ultimately became the standard for animal models simulating human cancer. He had administrative responsibility for several research programs within the Division of Clinical Immunology. He provided scientific leadership for basic research programs, scientific expertise in preclinical drug development studies, scientific and technical support for ongoing clinical trials. Concurrently, he was a Research Professor of Experimental Pathology at SUNY in Buffalo, New York. Dr. Goldrosen has trained dozens of doctoral and post-doctoral students who have gone on to be successful clinicians and scientists and to make important contributions to the oncology field.
Dr. Goldrosen officially assumed his position on June 4, 2001.